Upcoming Programs & Events
Coaching, Connections, and Coffee: Building Resilience During Tough Times
Thursday 10/15 @ 11am ET
Online
TOGETHER, TRANSFORMING LIVES
Can Do MS delivers health and wellness education programs to help families living with MS thrive.
Strengthen Families With MS
100% of your gift helps bring life-changing education programs to families in need.
RECENT NEWS
This September, show the world how you #ThriveWithMS to inspire others and spread awareness of multiple sclerosis
Can Do Multiple Sclerosis, a non-profit that delivers health and wellness education programs for families with MS, launched their annual, online campaign today that encourages people living with MS, as well as their friends and supporters, to share how they thrive with MS during September’s Can Do Month celebration.
Color Street Foundation pledges $100,000 to support MS awareness
For the month of August, the Color Street Foundation is pledging $100,000 to support awareness, research, and direct support programs for those who live with MS.
+
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
ROCKLAND, Mass., May 27, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced today the U.S. Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy and breastfeeding in the prescribing information for Rebif® (interferon beta-1a), in accordance with the FDA's Pregnancy and Lactation Labeling Rule (PLLR).
+
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA®
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that ZEPOSIA® (ozanimod) 0.92 mg, a new once-daily oral medication for adults for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, is now commercially available in the U.S. ZEPOSIA was approved by the U.S. Food and Drug Administration (FDA) on March 25, 2020.
+